Yasushi Tsuji1, Hideo Baba2, Koji Takeda3, Michiya Kobayashi4, Eiji Oki5, Masahiro Gotoh6, Kazuhiro Yoshida7, Mototsugu Shimokawa8, Yoshihiro Kakeji9, Keisuke Aiba10. 1. a Department of Medical Oncology , Tonan Hospital , Sapporo , Japan. 2. b Department of Gastroenterological Surgery , Kumamoto University , Kumamoto , Japan. 3. c Department of Clinical Oncology , Osaka City General Hospital , Osaka , Japan. 4. d Cancer Treatment Center , Kochi Medical School Hospital , Nankoku , Japan. 5. e Department of Surgery and Science , Kyushu University , Fukuoka , Japan. 6. f Cancer Chemotherapy Center , Osaka Medical College Hospital , Takatsuki , Japan. 7. g Department of Surgical Oncology , Gifu University , Gifu , Japan. 8. h Department of Cancer Information Research , National Hospital Organization Kyushu Cancer Center , Fukuoka , Japan. 9. i Division of Gastrointestinal Surgery , Kobe University Hospital , Kobe , Japan. 10. j Department of Internal Medicine, Division of Clinical Oncology and Hematology , The Jikei University School of Medicine , Tokyo , Japan.
Abstract
OBJECTIVES: Chemotherapy is an indispensable therapeutic approach for colorectal cancer both in the adjuvant and metastatic setting. Although chemotherapy-induced nausea and vomiting (CINV) is one of the most crucial adverse events, many aspects of CINV in patients with colorectal cancer remain unclear. METHODS: This multicenter, prospective, observational study analyzed the data of 190 colorectal cancer patients scheduled for moderately emetogenic chemotherapy (MEC). The patients recorded the incidence of CINV and severity of nausea by visual analogue scales daily for 7 days after receiving chemotherapy. RESULTS: All 190 patients received MEC and 99% of patients received antiemetic therapy in compliance with guidelines. Acute CINV was well controlled. 13 (6.8%) patients suffered from acute nausea and 4 (2.1%) experienced acute vomiting, whereas the prevalence of delayed CINV was relatively high. Delayed nausea occurred in 71 (37.4%) patients and delayed vomiting in 24 (12.6%). History of motion sickness was a significant independent risk factor for delayed nausea (Odd ratio 3.89, 95% confidence interval 1.49-10.19, p = 0.0056). CONCLUSIONS: The compliance with CINV guidelines in colorectal cancer chemotherapy was quite high and led to good control of chemotherapy-induced vomiting in Japan. However, the incidence of delayed nausea remained high in patients receiving MEC.
OBJECTIVES: Chemotherapy is an indispensable therapeutic approach for colorectal cancer both in the adjuvant and metastatic setting. Although chemotherapy-induced nausea and vomiting (CINV) is one of the most crucial adverse events, many aspects of CINV in patients with colorectal cancer remain unclear. METHODS: This multicenter, prospective, observational study analyzed the data of 190 colorectal cancerpatients scheduled for moderately emetogenic chemotherapy (MEC). The patients recorded the incidence of CINV and severity of nausea by visual analogue scales daily for 7 days after receiving chemotherapy. RESULTS: All 190 patients received MEC and 99% of patients received antiemetic therapy in compliance with guidelines. Acute CINV was well controlled. 13 (6.8%) patients suffered from acute nausea and 4 (2.1%) experienced acute vomiting, whereas the prevalence of delayed CINV was relatively high. Delayed nausea occurred in 71 (37.4%) patients and delayed vomiting in 24 (12.6%). History of motion sickness was a significant independent risk factor for delayed nausea (Odd ratio 3.89, 95% confidence interval 1.49-10.19, p = 0.0056). CONCLUSIONS: The compliance with CINV guidelines in colorectal cancer chemotherapy was quite high and led to good control of chemotherapy-induced vomiting in Japan. However, the incidence of delayed nausea remained high in patients receiving MEC.